RxDoctor Payments Data

David Allen, MD

Pulmonary Disease · Oklahoma City, OKNPI 1154398410

Payments from drug & device makers

$992in general payments, 2019–2025

Across 52 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$318
  • GSK$181
  • Sanofi$98
  • Mylan Specialty L.p.$75
  • United Therapeutics Corporation$66
  • AbbVie$59
  • plus $194 from 8 others

What the payments were for

  • Food & beverage$98099%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$992 in reported general payments places this provider in the 30th percentile of 133 pulmonary disease providers in Oklahoma.

See all pulmonary disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$101,096
Medicare patients
256
Services billed
883

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TracleerBosentan11$131,699
Trelegy ElliptaFluticasone/Umeclidin/Vilanter136$110,189
Fasenra PenBenralizumab19$107,651
RevatioSildenafil Citrate12$58,238
EliquisApixaban36$26,779
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$21,763
Teriparatide12$20,850
Breo ElliptaFluticasone/Vilanterol29$16,527
Ipratropium Bromide386$9,526
Spiriva RespimatTiotropium Bromide13$8,630
Spiriva HandihalerTiotropium Bromide12$8,567
SymbicortBudesonide/Formoterol Fumarate26$7,907
Montelukast Sodium201$4,029
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$3,732
Fluticasone Propionate243$3,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$181$148,480195 claims
PfizerEliquis$12$26,77936 claims
Boehringer IngelheimSpiriva Respimat$33$8,63013 claims
AstraZenecaSymbicort$318$7,90726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 133 pulmonary disease providers in Oklahoma.

Other pulmonary disease in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →